Very interesting new press release

No idea why the Intercept share price went down given that it’ll be much easier now to get a positive trial result with statistical significance on only one or other of the co-primary endpoints and it’s reduced the number of subjects required in total as well!

It certainly does raise the probability of success – I’m a Consultant Statistician as should know

The analysts at Leerink certainly don’t !

>>

http://www.fiercebiotech.com/node/473936?mkt_tok=eyJpIjoiWWpObE5UUmxaVE5rWTJFeSIsInQiOiJsczF3dnJFTlIzY3BlZmxDaHVPU3RNT3NEcUdSSnBvR3B2cUZYb21CbjMrenhxN1RUNW10U3pTYjA4QjRaSG1jN1lHT3VtVFJHVGpac0ZVTHl5bTZoU3MwaHA0NVg0OEVcL2R2bHd0M3BRVzhIcXM0cmdSSFN5enNHQVlIXC9sWk0zIn0%3D&mrkid=938224&utm_medium=nl&utm_source=internal#